Cancer Letters
Volume 229, Issue 1 , Pages 77-83 , 8 November 2005

A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection

  • Zhong-Zheng Zhu

      Affiliations

    • Department of Pathology, Eastern Hepatobiliary Surgery Hospital, No. 225 Changhai Road, 200438 Shanghai, People's Republic of China
    • ,
  • Wen-Ming Cong

      Affiliations

    • Department of Pathology, Eastern Hepatobiliary Surgery Hospital, No. 225 Changhai Road, 200438 Shanghai, People's Republic of China
    • Corresponding Author InformationCorresponding author. Tel./fax: +86 21 25070854.
    • ,
  • Shu-Fang Liu

      Affiliations

    • Department of Gastroenterology, Railway Hospital, Tongji University, 200072 Shanghai, People's Republic of China
    • ,
  • Zhi-Hong Xian

      Affiliations

    • Department of Pathology, Eastern Hepatobiliary Surgery Hospital, No. 225 Changhai Road, 200438 Shanghai, People's Republic of China
    • ,
  • Wei-Qing Wu

      Affiliations

    • Department of Pathology, Eastern Hepatobiliary Surgery Hospital, No. 225 Changhai Road, 200438 Shanghai, People's Republic of China
    • ,
  • Meng-Chao Wu

      Affiliations

    • Department of Pathology, Eastern Hepatobiliary Surgery Hospital, No. 225 Changhai Road, 200438 Shanghai, People's Republic of China
    • ,
  • Bin Gao

      Affiliations

    • National Institute on Alcohol Abuse and Alcoholism, National Institute of Health, Bethesda, MD 20852, USA
    • ,
  • Li-Fang Hou

      Affiliations

    • Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    • ,
  • Guan-Shan Zhu

      Affiliations

    • National Institute on Alcohol Abuse and Alcoholism, National Institute of Health, Bethesda, MD 20852, USA
    • Department of Infectious Diseases, Changhai Hospital, 200433 Shanghai, People's Republic of China

Received 31 January 2005 ,Revised 8 April 2005 ,Accepted 11 April 2005.

References 

  1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin. Liver Dis. 1999;19:271–285
  2. Kao JH, Chen DS. Recent research progress in hepatocellular carcinoma. J. Formos. Med. Assoc. 2002;101:239–248
  3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 2001;94:153–156
  4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  5. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 2002;31:339–346
  6. Buendia MA. Genetics of hepatocellular carcinoma. Semin. Cancer Biol. 2000;10:185–200
  7. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, Martinez de Pancorboa M. P14ARF gene alterations in human hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2004;16:19–26
  8. Yu MW, Yang SY, Pan IJ, Lin CL, Liu CJ, Liaw YF, et al. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J. Natl Cancer Inst. 2003;95:1485–1488
  9. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, et al. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology. 2001;121:1136–1144
  10. Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology. 2003;37:65–71
  11. Shin HD, Park BL, Kim LH, Jung JH, Kim JY, Yoon JH, et al. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum. Mol. Genet. 2003;12:901–906
  12. Yu MW, Chiu YH, Yang SY, Santella RM, Chern HD, Liaw YF, et al. Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Br. J. Cancer. 1999;80:598–603
  13. Yu MW, Pai CI, Yang SY, Hsiao TJ, Chang HC, Lin SM, et al. Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk. Gut. 2000;47:703–709
  14. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003;33:357–365
  15. Irarrazabal CE, Rojas C, Aracena R, Marquez C, Gil L. Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol. Lett. 2003;144:69–76
  16. Lee JM, Lee YC, Yang SY, Shi WL, Lee CJ, Luh SP, et al. Genetic polymorphisms of p53 and GSTP1,but not NAT2,are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int. J. Cancer. 2000;89:458–464
  17. Hiyama T, Tanaka S, Kitadai Y, Ito M, Sumii M, Yoshihara M, et al. p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int. J. Cancer. 2002;100:304–308
  18. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996;17:1313–1316
  19. Tsai MH, Lin CD, Hsieh YY, Chang FC, Tsai FJ, Chen WC, et al. Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope. 2002;112:116–119
  20. Kuroda Y, Tsukino H, Nakao H, Imai H, Katoh T. p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett. 2003;189:77–83
  21. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J. Biomed. Sci. 2003;10:430–435
  22. Chen YC, Xu L, Guo YL, Su HJ, Hsueh YM, Smith TJ, et al. Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan. J. Environ. Sci. Health Part A Tox. Hazard Subst. Environ. Eng. 2003;38:201–211
  23. Pierce LM, Sivaraman L, Chang W, Lum A, Donlon T, Seifried A, et al. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol. Biomarkers Prev. 2000;9:1199–1204
  24. Wu MT, Chen MC, Wu DC. Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett. 2004;205:61–68
  25. Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol. Cell Biol. Res. Commun. 2000;3:389–392
  26. Toruner GA, Ucar A, Tez M, Cetinkaya M, Ozen H, Ozcelik T. P53 codon 72 polymorphism in bladder cancer—no evidence of association with increased risk or invasiveness. Urol. Res. 2001;29:393–395
  27. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2004;13:2217–2224
  28. O'Connor DP, Kay EW, Leader M, Atkins GJ, Murphy GM, Mabruk MJ. p53 codon 72 polymorphism and human papillomavirus associated skin cancer. J. Clin. Pathol. 2001;54:539–542
  29. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29:697–702
  30. Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU, et al. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett. 2004;208:75–79
  31. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, de Pancorbo MM. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett. 2003;193:199–205
  32. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990;18:4961
  33. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet. 1981;2:1129–1133
  34. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 2002;347:168–174
  35. Slagle BL, Zhou YZ, Butel JS. Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas. Cancer Res. 1991;51:49–54
  36. Jia L, Wang XW, Harris CC. Hepatitis B virus X protein inhibits nucleotide excision repair. Int. J. Cancer. 1999;80:875–879
  37. Lee SG, Rho HM. Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene. 2000;19:468–471
  38. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 1995;9:41–47
  39. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA. 1994;91:2230–2234
  40. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–234

PII: S0304-3835(05)00387-3

doi: 10.1016/j.canlet.2005.04.014

Cancer Letters
Volume 229, Issue 1 , Pages 77-83 , 8 November 2005

Article Tools